Muscarinic receptor binding in central airway musculature in chronic airflow obstruction.
The hypothesis of an increased muscarinic receptor sensitivity in airway musculature of patients with chronic airflow obstruction (CAO) has been investigated by in vitro radioligand binding studies. The receptor binding profiles were determined in membrane homogenates of tracheal and main bronchial smooth muscle, as well as in segmental bronchial tissue preparations. The number of receptors was measured by binding of the radioactive muscarinic antagonist [3H]-(-)-quinuclidinyl benzilate ([3H]-(-)-QNB). The affinity for agonists was investigated by studying the inhibition of [3H]-(-)-QNB binding by the full muscarinic agonist methylfurtrethonium. Binding characteristics were determined (1) in tracheal smooth muscle from 7 patients with chronic airflow obstruction (2) in main bronchial smooth muscle of 5 patients with CAO and (3) in segmental bronchial tissue of 10 patients with CAO. The receptor binding properties were compared with values obtained on airway tissue from 31 subjects without CAO. Muscarinic receptors in smooth muscle preparations of trachea and main bronchus were present in normal density, and showed normal [3H]-(-)-QNB binding affinity and methylfurtrethonium binding properties. In segmental bronchial tissue preparations which contain smooth muscle and glandular tissue, also normal receptor numbers and [3H]-(-)-QNB affinity values were found. Morphometric examination of these preparations revealed normal amounts of smooth muscle and submucosal glands. This suggests that the excessive mucus production of CAO is not accompanied by an increased muscarinic receptor density in submucosal glands. These observations suggest unaltered muscarinic receptor characteristics in central airway smooth muscle of patients with chronic airflow obstruction.
van Koppen
C J
CJ
Department of Pharmacology, University of Nijmegen, The Netherlands.
Lammers
J W
JW
Rodrigues de Miranda
J F
JF
Beld
A J
AJ
van Herwaarden
C L
CL
van Ginneken
C A
CA
D000368:Aged; D001980:Bronchi / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008173:Lung Diseases, Obstructive / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D009116:Muscarine / Q000031:analogs & derivatives; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D010277:Parasympathomimetics; D011813:Quinuclidinyl Benzilate; D011976:Receptors, Muscarinic / Q000378:metabolism*; D012137:Respiratory System / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014132:Trachea / Q000187:drug effects / Q000378:metabolism
D010277:Parasympathomimetics; D011976:Receptors, Muscarinic; C008446:5-methylfurtrethonium; D011813:Quinuclidinyl Benzilate; D009116:Muscarine